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ABSTRACT Asthma management guidelines recommend adding a long-acting β2-agonist (LABA) or
increasing the dose of inhaled corticosteroid (ICS) as step-up therapy for patients with uncontrolled
asthma on ICS monotherapy. However, it is uncertain which option works best, which ICS particle size is
most effective, and whether LABA should be administered by separate or combination inhalers.
This historical, matched cohort study compared asthma-related outcomes for patients (aged 12–80 years)
prescribed step-up therapy as a ⩾50% extrafine ICS dose increase or add-on LABA, via either a separate
inhaler or a fine-particle ICS/LABA fixed-dose combination (FDC) inhaler. Risk-domain asthma control
was the primary end-point in comparisons of cohorts matched for asthma severity and control during the
baseline year.
After 1:2 cohort matching, the increased extrafine ICS versus separate ICS+LABA cohorts included 3232
and 6464 patients, respectively, and the fine-particle ICS/LABA FDC versus separate ICS+LABA cohorts
included 7529 and 15058 patients, respectively (overall mean age 42 years; 61–62% females). Over one
outcome year, adjusted OR (95% CI) for achieving asthma control were 1.25 (1.13–1.38) for increased ICS
versus separate ICS+LABA and 1.06 (1.05–1.09) for ICS/LABA FDC versus separate ICS+LABA.
For patients with asthma, increased dose of extrafine-particle ICS, or add-on LABA via ICS/LABA
combination inhaler, is associated with significantly better outcomes than ICS+LABA via separate inhalers.
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Introduction
For patients whose asthma is not controlled with low-to-moderate doses of inhaled corticosteroids (ICS),
the preferred initial step-up option in asthma management guidelines is the addition of a long-acting
β2-agonist (LABA), either as a fixed-dose combination (FDC) or via two separate inhalers, with further
step-up options including an increased dose of ICS [1, 2]. Until 2011, the British Thoracic Society/Scottish
Intercollegiate Network recommended ICS and LABA in either separate or combination inhalers [3].
However, previous research has shown that, for patients using separate ICS and LABA inhalers, problems
with adherence can result in LABA monotherapy, which has been associated with an increased risk of
death [4]. Despite this, there is little evidence or guidance in the literature regarding whether separate or
combination inhalers are preferred or recommended.
For adolescents and adults, the addition of LABA to ICS therapy often provides better symptom control
and less need for reliever therapy [5–7]. In randomised controlled trials, patients receiving LABA in
combination with ICS experienced improved lung function and symptom control compared with patients
receiving an increased ICS dose [6, 8–13]. Some of these trials assessed the effect of combination inhalers
compared with separate inhalers, but few statistically significant differences were observed [12]. However,
up to 95% of patients with asthma are not eligible for participation in randomised controlled trials because
of smoking, comorbidities or lung function impairment [14]. Furthermore, recruited patients benefit from
close follow-up during their participation in these trials, and adherence in these studies is therefore likely
to be higher than in the general patient population [15, 16]. Observational studies have indeed suggested
that combination inhalers improve adherence in real-life patients, which is likely to influence therapeutic
outcomes [17, 18]. Moreover, we have previously shown that an increased dose of ICS is as effective as
add-on LABA via FDC inhaler in a general population of patients with asthma [19].
Another variable that may affect outcomes is particle size. Previous randomised trials have often focused
on fine-particle ICS (mass median aerodynamic diameter 2–5 μm), such as fluticasone and budesonide,
whereas a substantial proportion of the general asthma patient population is prescribed extrafine-particle
ICS. Extrafine-particle ICS (e.g. beclomethasone, mass median aerodynamic diameter ∼1 μm), exhibits
significantly increased lung deposition compared with fine-particle ICS [20, 21]. Furthermore, real-life
research has suggested that treatment with extrafine-particle ICS results in similar or superior
asthma-related outcomes at lower prescribed doses compared with fine-particle ICS [22–25].
The objective of this retrospective matched cohort study was to evaluate the real-life effectiveness of
step-up asthma therapy with LABA added to ICS (any particle size) via separate inhalers compared with
either an increased dose of extrafine-particle ICS or with a fine-particle ICS/LABA FDC inhaler. Our
hypothesis was that, for adolescent and adult patients with evidence of persistent uncontrolled asthma,
step-up treatments with either increased extrafine-particle ICS or with fine-particle ICS/LABA FDC would
be a superior alternative to ICS and LABA in separate inhalers.
Methods
Data source and patients
This historical, matched cohort, comparative effectiveness study drew on two large UK databases: the
General Practice Research Database (GPRD), which is now part of the Clinical Practice Research Datalink
[26], and the Optimum Patient Care Research Database (OPCRD) (supplementary material) [27]. Both
databases are well described and have previously been used for respiratory research. The Independent
Scientific Advisory Committee approved the use of GPRD data for the purpose of this study, and the
OPCRD was approved by Trent Multi-Centre Research Ethics Committee (current NHS HRA approval
REC reference 15/EM/0150) for clinical research use. The study protocol was designed by an independent
steering committee and approved by the Anonymised Data Ethics Protocols and Transparency Committee,
which is the independent scientific advisory committee of Optimum Patient Care. This study was registered
at clinicaltrials.gov (identifier NCT01697722).
Eligible patients (aged 12–80 years) had at least 2 years of continuous data within the study window: a
1-year baseline period before the index date to control for baseline confounders, and a 1-year outcome
period following the index date during which primary and secondary outcome parameters were assessed.
During the baseline year, patients had at least two prescriptions for asthma therapy, including at least one
for ICS. Exclusion criteria included a recorded diagnosis of chronic obstructive pulmonary disease (COPD)
or any chronic respiratory disease other than asthma, as well as a history of smoking for patients between
61 and 80 years of age. This age limit was chosen in order to minimise the inclusion of patients with COPD
misdiagnosed as asthma, since the proportion of patients with airflow obstruction who also have COPD
increases to ∼40% for patients aged 60–69 years and the diagnoses can be difficult to differentiate [28–30].
The index date was defined as the date ICS treatment was stepped up by one of the following three
options: 1) ⩾50% increase in ICS dose of extrafine-particle beclomethasone dipropionate (ICS step-up);
ERJ Open Res 2016; 2: 00106-2015 | DOI: 10.1183/23120541.00106-2015 2
ASTHMA | D.B. PRICE ET AL.
2) addition of LABA via FDC of fine-particle ICS and LABA with no change in ICS dose (ICS/LABA
FDC); or 3) addition of LABA by separate inhaler, with no change in ICS drug substance, device type or
daily ICS dose in beclomethasone equivalents (separate ICS+LABA). During the baseline period, patients
in all cohorts were prescribed either fine-particle or extrafine-particle ICS. During the outcome period,
patients in the ICS step-up cohort were prescribed extrafine-particle ICS, patients in the ICS/LABA FDC
cohort received fine-particle ICS, and patients in the separate ICS+LABA cohort received either
fine-particle or extrafine-particle ICS (supplementary material and table S2). The study period covered
14 years between January 1997 and January 2011.
Outcome measures
The primary effectiveness end-point was risk-domain asthma control, i.e. no hospital admission, no
emergency department attendance, no general practice attendance for lower respiratory tract infections, and
no oral corticosteroid prescriptions as previously described [23, 25]. Secondary end-points included the
number of severe exacerbations, number of acute respiratory events and treatment stability (table 1) [31, 32].
The total daily coverage of β2-agonist (short-acting β2-agonist (SABA)+LABA) was calculated as the
dispensed amount divided by 365 and defining two puffs of SABA (albuterol 200 μg or terbutaline 500 μg)
as lasting 4 h, and two puffs of LABA via pressurised metered-dose inhaler or one puff of LABA via dry
powder inhaler as lasting 12 h.
Statistical analysis
The statistical analysis plan was defined before data analysis, following a priori defined standard procedures
of the research team. After patient selection (figure S1), an exploratory analysis was carried out for all
TABLE 1 Study definitions: database-derived outcome measures and matching criteria
Primary end-point
Risk-domain asthma control includes all of the following:
1. No asthma-related# hospital attendance or admission, ED attendance, out-of-hours attendance, or
outpatient hospital attendance, and
2. No GP consultation for lower respiratory tract infection¶ with resultant antibiotic prescription¶, and
3. No prescription for acute course of oral corticosteroids
Secondary end-points
Number of severe exacerbations+, defined as any of the following [31]:
1. Asthma-related# hospital attendance or admission or ED attendance, or
2. Acute course of oral corticosteroids
Number of acute respiratory events, defined as any of the following:
1. Asthma-related# hospital attendance or admission or ED attendance, or
2. Acute course of oral corticosteroids, or
3. GP consultation for lower respiratory tract infection¶
Treatment stability, includes all of the following:
1. Asthma control (primary end-point, see above) and
2. No treatment change, defined additional therapy or change in therapy as
a) Increased ICS dose (by ⩾50%), or
b) Use of additional therapy, such as LABA, LTRA or theophylline
Matching criteria: patients were matched at the index prescription date by
1. Sex (male/female)
2. Age (±5 years)
3. Last ICS daily dose prescribed before index date prescription (categorised as 1–50 μg/51–100 μg/
101–200 μg/201–300 μg/301–400 μg/>400 μg in extrafine beclomethasone equivalents§)
4. Asthma control (defined as primary end-point) during baseline year (controlled/not controlled)
5. Mean SABA daily dose during baseline yearƒ (categorised as 0 μg/1–200 μg/201–400 μg/>400 μg)
6. Asthma consultation(s) without severe exacerbation (0/1/⩾2)
ED: emergency department; GP: general practitioner; ICS: inhaled corticosteroid; LABA: long-acting
β2-agonist; LTRA: leukotriene receptor antagonist; SABA: short-acting β2-agonist.
#: defined as all events with
a lower respiratory code, including all asthma codes and lower respiratory tract infection codes; ¶: identified
as GP consultations with a code for lower respiratory tract infection Read code in the database; +: hospital
attendance/admission and/or an oral corticosteroid course within a 2-week window were considered as one
exacerbation; §: doses of budesonide and the large-particle beclomethasone (Clenil Modulite, Chiesi,
Manchester, UK) were halved, and fluticasone doses of 250 μg and 500 μg were treated as equivalent to
extrafine-particle beclomethasone 200 and 400 μg; ƒ: SABA daily dose was defined as total prescribed SABA
during baseline year divided by 365. Reproduced from [19] with permission from the publisher.
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baseline variables, and statistical analyses were carried out via primary and secondary effectiveness outcomes.
The analysis of baseline data revealed clinical and statistically significant differences between cohorts. A
matched cohort analysis was therefore carried out using demographic and clinical matching criteria, as
outlined in table 1. To maximise cohort sizes, a 1:2 matching was carried out between the extrafine-particle
ICS step-up and the separate ICS+LABA cohorts on the one hand, and between the FDC fine-particle ICS/
LABA and the separate ICS+LABA cohorts on the other hand. Summary statistics were used to describe all
matched baseline and outcome variables, both for the combined patient group and separated into treatment
groups. To reduce the possibility of selection bias, numerous potential confounding variables were assessed,
including some that were identified during previous respiratory research from the research team: baseline
differences between treatment cohorts (p<0.10) were considered potentially important, as well as baseline
variables that were predictive (p<0.05) of each effectiveness outcome in multivariable analyses. Variables that
met these criteria were examined for collinearity, as well as for clinical importance, to select those used as
potential confounders in regression modelling of outcomes.
Two-way comparisons between cohorts, both baseline and outcome variables, were analysed by
conditional logistic regression. The adjusted odds of achieving risk-domain asthma control were compared
between treatment groups using conditional logistic regression models, with asthma control used as the
dependent variable, and treatment and potential confounding factors as explanatory variables. Variables
with p<0.10 were included as potential confounding factors. The same method was employed to determine
the adjusted odds of achieving treatment stability. The total number of severe exacerbations during the
outcome period was compared between matched treatment groups using a conditional Poisson regression
model, and exacerbation rate ratios were determined. The model used empirical standard errors for more
robust confidence intervals, and adjustments were made for potential baseline confounders. Statistically
significant results were defined as p<0.05. Analyses were carried out using SPSS Statistics (version 19; IBM,
Armonk, NY, USA), SAS (version 9.3; SAS Institute, Cary, NC, USA), and Microsoft Office Excel 2007
(Microsoft Corp. Redmond, WA, USA).
Results
Extrafine-particle ICS dose step-up compared with ICS and LABA in separate inhalers
Information on the unmatched patient population is available in the supplementary material and table S1.
After patient selection (figure S1) and 1:2 matching there were 3232 patients in the extrafine ICS step-up
cohort and 6464 patients in the separate ICS+LABA cohort (table 2, table S2, supplementary material).
The mean age was 42 years and 61% were female. The cohorts were well matched for asthma-related
parameters, and statistically significant differences between cohorts were small (table 2). The mean ICS
dose prescribed on the index date for the extrafine ICS step-up cohort was approximately twice that for
the separate ICS+LABA cohort (394 versus 194 μg·day−1; p<0.001).
Over the outcome year, the proportion of patients who achieved risk-domain asthma control increased
from 65% during the baseline year to 75% and 71% in the extrafine ICS step-up and separate ICS+LABA
cohorts, respectively. Therefore, a significantly higher proportion of patients prescribed extrafine ICS
step-up achieved risk-domain asthma control compared with those prescribed separate ICS+LABA, and
fewer of these patients experienced severe asthma exacerbations or acute respiratory events or required a
change in therapy (table 3). The adjusted odds ratios for achieving risk-domain asthma control and
treatment stability were significantly greater with extrafine ICS step-up compared with separate
ICS+LABA. For risk-domain asthma control, the OR (95% CI) was 1.25 (1.13–1.38), while the rates of
severe exacerbations or acute respiratory events were significantly lower (figure 1).
The daily dose of SABA during the outcome year was significantly higher in the extrafine ICS step-up
cohort than in the separate ICS+LABA cohort, although the median was the same (219 μg·day−1).
However, total β2-agonist coverage was significantly longer for the separate ICS+LABA cohort than for the
extrafine ICS step-up cohort (table 3, figure 2a).
Fine-particle ICS/LABA combination inhaler compared with ICS and LABA in separate inhalers
After matching, there were 7529 patients in the fine-particle ICS/LABA combination cohort and 15058
patients in the separate ICS+LABA cohort. Most of the baseline differences between cohorts were small,
although several were statistically significant because of the large cohort sizes (table 2, table S2,
supplementary material). For the patients who received separate ICS+LABA inhalers, the mean index date
was 2 years earlier than for those who received fine-particle ICS/LABA FDC inhalers. Probably as a
consequence of this, fewer patients in the separate ICS+LABA cohort had recorded smoking data (83%
versus 92% in the ICS/LABA FDC cohort) (table 2).
During the outcome year, the proportion of patients who achieved risk-domain asthma control increased
from 58% during the baseline year to 72% in the fine-particle ICS/LABA cohort and 68% in the separate
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ICS+LABA cohort. Risk-domain asthma control and treatment stability were significantly higher for
patients who received fine-particle ICS/LABA inhalers compared with separate ICS+LABA inhalers. For
risk-domain asthma control, the OR (95% CI) was 1.06 (1.05–1.09) and the risk of severe exacerbations
and acute respiratory events was significantly lower (figure 3, table 3). The proportion of patients changing
treatment was also lower in the fine-particle ICS/LABA FDC cohort than in the separate ICS+LABA
cohort (table 3).
The daily dose of SABA was significantly lower, and the daily β2-agonist coverage (SABA+LABA) was
significantly higher, for the fine-particle ICS/LABA FDC cohort compared with the separate ICS+LABA
cohort (table 3, figure 2b).
Discussion
This study of a real-life patient population showed that the odds of achieving risk-domain asthma control
and treatment stability were significantly higher with an increased dose of extrafine-particle ICS or with
fine-particle ICS/LABA FDC inhalers, as compared with ICS and LABA via separate inhalers.
TABLE 2 Baseline demographic and clinical characteristics for two two-way comparisons of a step-up in asthma therapy using
an increased dose of extrafine-particle ICS or a fine-particle ICS/LABA combination inhaler, compared with add-on LABA in a
separate inhaler
Characteristics Extrafine ICS step-up FDC fine-particle ICS/LABA
ICS step-up Separate
ICS+LABA
FDC
ICS/LABA
Separate
ICS+LABA
Subjects n 3232 6464 7529 15058
Female# 1959 (60.6) 3918 (60.6) 4689 (62.3) 9378 (62.3)
Age at index date years# 42.4±16.4 42.3±16.4 42.1±16.1 42.2±15.9*
Smoking status¶
Current smoker 625 (22.3) 1165 (21.5)*** 1564 (22.7) 2992 (24.0)***
Ex-smoker 503 (18.0) 956 (17.7) 1255 (18.2) 2190 (17.6)
Nonsmoker 1673 (59.7) 3291 (60.8) 4076 (59.1) 7283 (58.4)
Nonsmokers aged 61–80 years 426 (13.2) 826 (12.8) 878 (11.7) 1694 (11.2)
Risk-domain asthma control# 2094 (64.8) 4188 (64.8) 4400 (58.4) 8800 (58.4)
Severe exacerbations
0 2412 (74.6) 4745 (73.4)* 5244 (69.7) 10225 (67.9)***
1 573 (17.7) 1175 (18.2) 1550 (20.6) 3186 (21.2)
2 167 (5.2) 378 (5.8) 499 (6.6) 1045 (6.9)
⩾3 80 (2.5) 166 (2.6) 236 (3.1) 602 (4.0)
Acute respiratory events
0 2124 (65.7) 4218 (65.3) 4522 (60.1) 8907 (59.2)
1 701 (21.7) 1391 (21.5) 1859 (24.7) 3725 (24.7)
2 267 (8.3) 560 (8.7) 731 (9.7) 1473 (9.8)
⩾3 140 (4.3) 295 (4.6) 417 (5.5) 953 (6.3)
Mean daily SABA dose#
0 μg·day−1 131 (4.1) 262 (4.1) 208 (2.8) 416 (2.8)
1–200 μg·day−1 1318 (40.8) 2636 (40.8) 2563 (34.0) 5126 (34.0)
201–400 μg·day−1 814 (25.2) 1628 (25.2) 2022 (26.9) 4044 (26.9)
>400 μg·day−1 969 (30.0) 1938 (30.0) 2736 (36.3) 5472 (36.3)
Last ICS dose before index date μg·day−1
#,+
193±49 194±54*** 295±187 293±185*
ICS dose at index date μ·day−1 394±98 194±53*** 301±194 292±184***
Asthma consultations/severe exacerbations#
0 1157 (35.8) 2314 (35.8) 2351 (31.2) 4702 (31.2)*
1 1136 (35.1) 2272 (35.1) 2542 (33.8) 5084 (33.8)
2 629 (19.5) 1126 (17.4)*** 1603 (21.3) 3048 (20.2)
⩾3 310 (9.6) 752 (11.6) 1033 (13.7) 2224 (14.8)
Data are presented as n (%) or mean±SD, unless otherwise stated. Additional baseline data can be found in table S2. ICS: inhaled
corticosteroids; LABA: long-acting β2-agonist; FDC: fixed-dose combination; SABA: short-acting β2-agonist.
#: matching variable; ¶: data were
available for 2801 (86.7%) and 5412 (83.7%) patients in the ICS and separate ICS+LABA cohorts, respectively, and for 6895 (91.6%) and 12465
(82.8%) in the ICS/LABA combination and separate ICS+LABA cohorts, respectively; +: for the purposes of matching, doses of budesonide and
large-particle beclomethasone (Clenil Modulite, Chiesi) were halved, and 250 and 500 μg of fluticasone were set to be equivalent to 200 and
400 μg of extrafine beclomethasone, respectively. At the index date, ICS doses are reported as half budesonide doses, while extrafine
beclomethasone and fluticasone doses are reported without modification. *: p⩽0.05, ***p<0.001, conditional logistic regression for two-way
comparison between cohorts.
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Furthermore, the rates of severe exacerbations and acute respiratory events were significantly lower with
increased doses of extrafine-particle ICS or fine-particle ICS/LABA FDC inhalers than with separate
ICS+LABA inhalers. The total β2-agonist coverage (adding hours covered by SABA+LABA) was
significantly longer for patients prescribed add-on LABA.
National and international guidelines recommend add-on LABA as the first step-up of asthma therapy.
Until 2011 (the last year of our study period) the recommendation of British guidelines for add-on LABA
was either via ICS/LABA FDC inhaler or ICS+LABA via separate inhalers [3, 33]. In agreement with this,
add-on LABA was the most commonly prescribed step-up therapy in the current study. Of the 35356
patients in the unmatched cohorts who met the eligibility criteria, 84% were prescribed add-on LABA, of
whom more than two-thirds received ICS and LABA in separate inhalers.
Asthma management guidelines are often predominantly based on randomised controlled trials that
exclude a large proportion of patients. Although the data are not always clear, several reports have
suggested that there is no difference in efficacy between add-on LABA in combination or in separate
inhalers [16, 33, 34]. This could partly be due to generally high adherence in these studies, which may
therefore not reflect the situation in the general patient population of asthma patients, where adherence
tends to be relatively low [15, 35, 36]. Differences in adherence probably contribute to the discrepancy
between the efficacy shown in controlled trials and the effectiveness observed in real-life studies [19, 37,
38]. Real-life studies have indeed suggested that FDC inhalers can make a substantial contribution to aid
refill persistence [18], and that patients on these inhalers are less likely to require rescue medication than
TABLE 3 Results from the 1-year outcome period from matched cohorts comparing a step-up in asthma therapy, using either
an increased dose of extrafine-particle ICS, or a fine-particle ICS/LABA combination inhaler versus the addition of LABA to ICS
in a separate inhaler
Outcome Extrafine ICS step-up p-valueƒ FDC fine-particle ICS p-valueƒ
ICS step-up Separate ICS+LABA FDC ICS/LABA Separate ICS+LABA
Subjects n 3232 6464 7529 15058
Risk-domain asthma control 2436 (75.4) 4573 (70.7) <0.001 5408 (71.8) 10170 (67.5) <0.001
Severe exacerbation
0 2692 (83.3) 5101 (78.9) <0.001 6110 (81.2) 11441 (76.0) <0.001
1 393 (12.2) 925 (14.3) 971 (12.9) 2313 (15.4)
2 85 (2.6) 259 (4.0) 268 (3.6) 726 (4.8)
⩾3 62 (1.9) 179 (2.8) 180 (2.4) 578 (3.8)
Acute respiratory events
0 2464 (76.2) 4656 (72.0) <0.001 5495 (73.0) 10350 (68.7) <0.001
1 528 (16.3) 1196 (18.5) 1343 (17.8) 2939 (19.5)
2 143 (4.4) 355 (5.5) 404 (5.4) 976 (6.5)
⩾3 97 (3.0) 257 (4.0) 287 (3.8) 793 (5.3)
Treatment stability 2111 (65.3) 3487 (53.9) <0.001 4626 (61.4) 7862 (52.2) <0.001
⩾1 asthma-related hospital attendance 10 (0.3) 50 (0.8) 0.008 29 (0.4) 82 (0.5) 0.11
⩾1 antibiotic prescriptions for LRTI 387 (12.0) 815 (12.6) 0.56 1050 (13.9) 2063 (13.7) 0.99
⩾1 prescription for oral corticosteroids 530 (16.4) 1343 (20.8) <0.001 1385 (18.4) 3557 (23.6) <0.001
Treatment change# 589 (18.2) 1814 (28.1) <0.001 1433 (19.0) 4087 (27.1) <0.001
Increase in ICS dose¶ 98 (3.0) 1294 (20.0) <0.001 1141 (15.2) 2445 (16.2) 0.034
Additional therapy 581 (18.0) 1385 (21.4) <0.001 469 (6.2) 3344 (22.2) <0.001
ICS dose exposure μg·day−1¶ 274 (164–438) 155 (65–247) <0.001 197 (115–345) 192 (96–329) 0.008
Daily SABA dose μg·day−1 219 (110–548) 219 (110–438) <0.001 219 (110–438) 274 (110–548) <0.001
Daily β2-agonist coverage h
+ 3.3 (1.1–7.7) 10.4 (5.1–19.1) <0.001 19.3 (10.5–28.7) 11.8 (5.9–20.3) <0.001
Change from baseline h 0.6 (−0.5–2.3) 7.0 (2.9–14.7) <0.001 15.2 (7.4–23.7) 7.6 (2.9–15.2) <0.001
Spacer device prescribed 486 (15.0) 1182 (18.3) <0.001 985 (13.1) 2926 (19.4) <0.001
Oropharyngeal candidiasis§ 155 (4.8) 321 (5.0) 0.72 396 (5.3) 819 (5.4) 0.57
Data are presented as n (%) or median (interquartile range), unless otherwise stated. ICS: inhaled corticosteroids; LABA: long-acting
β2-agonist; FDC: fixed-dose combination; LRTI: lower respiratory tract infection; SABA: short-acting β2-agonist.
#: patients could have more
than one change in therapy (and both increased ICS dose and additional therapy) during the year. Additional therapy could include combination
ICS/LABA inhaler (for ICS step-up cohort), separate LABA inhaler, leukotriene receptor antagonist and theophylline; ¶: the dose of budesonide
was halved for equivalence with extrafine beclomethasone and fluticasone, for which actual doses were used in the analyses. Daily ICS dose
exposure was calculated as the dispensed amount divided by 365. In the separate ICS+LABA cohort, 9–10% of patients were prescribed
extrafine beclomethasone during the baseline period and 10–11% during the outcome period; +: defined as the dispensed amount divided by
365 and defining two puffs of SABA as lasting 4 h, and two puffs of LABA via pressurised metered-dose inhaler or one puff of LABA via dry
powder inhaler as lasting 12 h; §: diagnosis of or therapy for oropharyngeal candidiasis (thrush); : p-value for conditional logistic regression.
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those using separate inhalers [17]. Indeed, the current results show a substantial advantage of fine-particle
ICS/LABA FDC inhalers compared with separate inhalers.
An alternative step-up option to add-on LABA is an increased dose of ICS, which has previously been
associated with a reduction in serious adverse events and hospitalisation [39]. Our previous historical
matched cohort study has shown that, in a general population of patients with asthma, an increased dose
of extrafine-particle ICS is as effective as fine-particle ICS/LABA in a FDC inhaler [19]. Furthermore, the
current study shows that an increased dose of extrafine ICS is significantly more effective than add-on
LABA via separate inhalers. A potential concern of ICS step-up might be that this leads to increased use of
reliever therapy. Although the statistical test shows that the daily dose of SABA was higher for patients
prescribed increased extrafine ICS compared with those prescribed separate ICS+LABA, the median daily
SABA dose was the same in both cohorts, suggesting that there is no real clinical difference between the
groups. In contrast, the median daily SABA dose was substantially higher for patients prescribed separate
ICS+LABA than for those prescribed fine-particle ICS/LABA in FDC inhalers (274 and 219 μg·day−1,
respectively). Furthermore, for total β2-agonist coverage (SABA+LABA), the exposure was significantly
longer for patients prescribed add-on LABA (median 3 h in the ICS step-up versus 10–19 h in the add-on
Risk for extrafine-particle ICS step-up
0.6 0.8
Lower with ICS step-up Higher with ICS step-up
Separate ICS+LABA = 1.00
Risk-domain asthma control 
OR
Treatment stability
OR
Severe exacerbation
RR
Acute respiratory event
RR
1.25 (1.13–1.38)#
1.63 (1.50–1.79)¶
0.79 (0.70–0.88)+
0.85 (0.78–0.93)§
1.0 1.2 1.5 2.0
FIGURE 1 Adjusted outcome measures comparing a step-up in asthma therapy using an increased dose of
extrafine-particle inhaled corticosteroids (ICS) versus the addition of a long-acting β2-agonist (LABA) to ICS in
a separate inhaler. Data show the adjusted odds ratio (OR) or rate ratio (RR) with 95% CI. Variables have been
adjusted for the following. #: number of oral corticosteroid prescriptions; ¶: smoking status and number of
oral corticosteroid prescriptions; +: smoking status and number of severe exacerbations during baseline year;
§: smoking status, number of oral corticosteroid prescriptions and number of primary care consultations.
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FIGURE 2 Comparison of total β2-agonist coverage for patients prescribed a) an increased dose of extrafine
inhaled corticosteroids (ICS) versus ICS+long-acting β2-agonist (LABA) in separate inhalers or b) fixed-dose
combination (FDC) of fine-particle ICS/LABA inhalers versus ICS+LABA in separate inhalers. Data are
presented as coverage in hours per 24 h, where the total daily coverage of β2-agonist (short-acting β2-agonist
(SABA)+LABA) was calculated as the annual dispensed amount divided by 365 and two puffs of SABA
(albuterol 200 μg or terbutaline 500 μg) were defined as lasting 4 h, and two puffs of LABA via pressurised
metered-dose inhaler or one puff of LABA via dry powder inhaler were defined as lasting 12 h.
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LABA cohorts). Therefore, an ICS dose step-up does not appear to result in any substantial increase in
SABA prescription, while total β2-agonist exposure increases substantially with add-on LABA.
In randomised controlled trials of bronchodilators, the primary end-point tends to be lung function, and
patients generally have to demonstrate β2-agonist reversibility to be included. The trials are also often
limited in timescale, and most require patients with stable asthma whose exacerbation risk is low. In this
context, the current study has several strengths. The findings depict clinically relevant real-life outcomes
for asthma therapy in UK primary care, the patient group is larger than most controlled trials, and the
1-year follow-up is likely to minimise seasonal variation and capture less frequent outcomes, such as
exacerbations. We did not exclude active smokers (15–24% of each cohort, except in the 61–80-year-old
age group), patients did not have to demonstrate β2-agonist reversibility to be included, and ∼25% of
patients in each cohort had rhinitis, which is a risk factor for poor asthma control [40]. Therefore, the
analysed patient group appears to be representative of the general UK asthma population, and this
improves generalisability of the study findings to general practice.
Our primary end-point of risk-domain asthma control was designed to capture the absence of asthma
exacerbations during the outcome year. This composite data outcome has been used in previous research
[19, 24] and is in line with factors identified by expert working groups as being reflective of the future risk
component of asthma control [31, 32, 41]. Although we conducted a matched cohort analysis, and
confounding was eliminated to the greatest possible extent with adjusted analyses, we acknowledge that the
use of matching may increase the risk of selection bias [42], and ignoring the matching variables may
produce a certain population causal effect [43]. Similar to other historical cohort studies, this one is also
limited by the fact that causal relationships cannot be inferred from the observed associations, and the
possibility of unrecognised confounding factors remains. Nevertheless, we believe that, although slight
baseline differences might still be present, they are unlikely to be of clinical significance.
For patients receiving ICS and LABA in separate inhalers, poor adherence to the ICS component can be
associated with risks. An investigation into asthma deaths in the UK found that 6% of patients prescribed
LABA in separate inhalers were not prescribed any ICS throughout the year, and an additional 12% had
significant gaps in ICS prescribing, suggesting that approximately one in five of these patients were
exposed to the increased risks associated with LABA monotherapy [3, 4]. In clinical practice, it is generally
considered that combination inhalers improve adherence, and they guarantee that LABA is not taken
without ICS [2]. Our results provide real-life evidence to support the notion that either ICS step-up or
add-on LABA via FDC inhalers is more effective than ICS and LABA in separate inhalers, which is the
least desirable step-up option in a general patient population. The importance of this information is
emphasised by the fact that more than two-thirds of patients prescribed add-on LABA received it via
separate inhalers.
Risk for FDC ICS/LABA
0.6 0.8
Lower with FDC ICS/LABA Higher with FDC ICS/LABA
Separate ICS+LABA = 1.00
Risk-domain asthma control
OR
Treatment stability
OR
Severe exacerbation
RR
Acute respiratory event
RR
1.06 (1.05–1.09)#
1.20 (1.16–1.27)¶
0.80 (0.74–0.85)+
0.87 (0.82–0.93)§
1.0 1.2 1.5 2.0
FIGURE 3 Adjusted outcome measures comparing a step-up in asthma therapy using a fixed-dose
combination (FDC) inhaler containing fine-particle inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)
versus the addition of LABA to ICS in a separate inhaler. Data show the adjusted odds ratio (OR) or rate ratio
(RR) with 95% CI. Variables have been adjusted for the following. #: smoking status, number of primary care
consultations and medication possession ratio; ¶: smoking status, adherence to ICS therapy, number of
nonasthma-related consultations and number of acute respiratory events; +: number of acute respiratory
events (categorised) and year of index date; §: number of acute respiratory events (categorised), year of index
date and number of primary care consultations.
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In conclusion, this real-life study of a broad general population of young people and adults with persistent
asthma suggests that step-up therapy, by increasing the dose of extrafine-particle ICS or by adding LABA
in FDC inhalers, is a better approach than prescribing ICS and LABA in separate inhalers. Whether this is
a strategy that will work better in some patient subgroups, e.g. patients with impaired therapeutic response
to β2-agonists or those with frequent exacerbations, is a question for further study.
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